Solventum Corporation (SOLV) Earnings Call Transcripts

Solventum Corporation's Latest Earnings Call - September 9, 2026

In the Q2 2026 earnings call, Solventum Corporation (SOLV:US) reported a revenue increase of 3.7% year-over-year, aligning with management's guidance of 2.5% to 3% for the full year. The company announced plans to separate its HIS segment, which is expected to dilute operating margins by approximately 400 basis points, but management remains confident in achieving long-term growth targets of 4% to 5% by 2028 for the remaining MedSurg and Dental businesses. Despite the HIS separation, management emphasized that the overall market growth for these segments remains intact, and they are poised for future product launches that could drive further revenue growth.

Reported metrics

Guidance from management

Management maintained the long-range plan growth target of 4% to 5% by 2028, despite the HIS separation. They expect to provide a new long-range plan at the Investor Day in March 2027.

What management said

Yes. Probably the biggest thing you almost want to just say, just add water because you have everything you kind of need, and adding the water for us is the infrastructure that we have on a global basis. We already play in the same customer call point. We already have these relationships. 60% of the time Restrata is used, they use it in concert with negative pressure wound therapy. So we have the infrastructure, we h...

No, I'd just say great line of questions. I'm very pleased. I always say that I'm happy, but not satisfied with the improvements that we've made. I want everyone to know that we have runway. We're in great markets. We're focused in those markets and our growth drivers and those subcategories to growth drivers are in place and moving in the right direction. And I'm really looking forward to the Investor Day in March. ...

What analysts pressed on

Analysts expressed concerns about the potential EPS dilution from the HIS separation, estimating around $1 of dilution. There were also worries about the impact of the tariff refund not recurring in 2027, which could hinder EPS growth.

Main topics on the call

• HIS Separation — Management confirmed the decision to separate the HIS business, stating, "it's not suited for us as it is for somebody else." This strategic move is expected to enhance focus on core MedTech operations, despite anticipat...
• Revenue Growth Guidance — Solventum raised its full-year organic growth guidance from 2% to 3% to 2.5% to 3%. CEO Bryan Hanson noted, "we're already approximating that guidance," indicating strong momentum in the first half of the year.
• Operating Margin Outlook — Management acknowledged that the HIS separation will be dilutive to operating margins, but CFO Wayde McMillan stated, "we expect to be improving sales growth and operating margin expansion each year," signaling confidenc...
• Product Launches — The company plans to launch nearly 20 new products by Q1 2028, focusing on areas such as advanced wound care and dental aesthetics. Management highlighted that these innovations are crucial for driving growth in the MedS...

Read the full Solventum Corporation transcript (September 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 23 Solventum Corporation earnings call transcripts on record, spanning March 19, 2024 to September 9, 2026. Based on this history, Solventum Corporation reports quarterly. The most recent call on file is dated September 9, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

SOLV

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

23

First call

March 19, 2024

Most recent

September 9, 2026

Reporting cadence

quarterly